Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)

References

• Parola M, Pinzani M. Pathophysiology of organ and tissue fibrosis. Mol Aspects Med. 2019;65:1.
   PubMed Web of Science ®Google Scholar
• Distler JHW, Gyorfi AH, Ramanujam M, et al. Shared and distinct mechanisms of fibrosis. Nat Rev Rheumatol. 2019;15(12):705–730.
   PubMed Web of Science ®Google Scholar
• Bos S, Laukens D. Metabolic modulation during intestinal fibrosis. J Dig Dis. 2020;21(6):319–325.
   PubMed Web of Science ®Google Scholar
• Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–1699.
   PubMed Web of Science ®Google Scholar
• Chanda D, Otoupalova E, Smith SR, et al. Developmental pathways in the pathogenesis of lung fibrosis. Mol Aspects Med. 2019;65:56–69.
   PubMed Web of Science ®Google Scholar
• Novo E, Bocca C, Foglia B, et al. Liver fibrogenesis: un update on established and emerging basic concepts. Arch Biochem Biophys. 2020 Aug 15;689:108445.
   PubMed Web of Science ®Google Scholar
• Yang L. How acute kidney injury contributes to renal fibrosis. Adv Exp Med Biol. 2019;1165:117–142.
   PubMed Web of Science ®Google Scholar
• Tsutsumi T, Adachi M, Nikawadori M, et al. Presence of bioactive lysophosphatidic acid in renal effluent of rats with unilateral ureteral obstruction. Life Sci. 2011 Aug 1;89(5–6):195–203.
   PubMed Web of Science ®Google Scholar
• Hinderer S, Schenke-Layland K. Cardiac fibrosis - A short review of causes and therapeutic strategies. Adv Drug Deliv Rev. 2019;146:77–82.
   PubMed Web of Science ®Google Scholar
• Liu YM, Nepali K, Liou JP. Idiopathic pulmonary fibrosis: current status, recent progress, and emerging targets. J Med Chem. 2017;60(2):527–553.
   PubMed Web of Science ®Google Scholar
• Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Feb 15;183(4):431–440.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Kolb M. The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy? Eur Respir J. 2018;51(1):1702420.
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–1769.
   PubMed Web of Science ®Google Scholar
• Marshall DC, Salciccioli JD, Shea BS, et al. Trends in mortality from idiopathic pulmonary fibrosis in the European Union: an observational study of the WHO mortality database from 2001-2013. Eur Respir J. 2018;51(1):1701603.
   PubMed Web of Science ®Google Scholar
• Hutchinson J, Fogarty A, Hubbard R, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015;46(3):795–806.
   PubMed Web of Science ®Google Scholar
• Hutchinson JP, McKeever TM, Fogarty AW, et al. Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century. Ann Am Thorac Soc. 2014;11(8):1176–1185.
   PubMedGoogle Scholar
• Sgalla G, Biffi A, Richeldi L. Idiopathic pulmonary fibrosis: diagnosis, epidemiology and natural history. Respirology. 2016;21(3):427–437.
   PubMed Web of Science ®Google Scholar
• Raghu G, Chen S-Y, Yeh W-S, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. Lancet Respir Med. 2014;2(7):566–572.
   PubMed Web of Science ®Google Scholar
• Glassberg MK. Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape. Am J Manag Care. 2019;25(11 Suppl):S195–S203.
   PubMedGoogle Scholar
• Ipatova AY, Koerner PH, Miller RT, et al. Retrospective analysis of medication utilization and clinical outcomes in patients with idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone. Clin Med Insights Circ Respir Pulm Med. 2019;13:1179548419834922.
   Web of Science ®Google Scholar
• Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis - FDA review of pirfenidone and nintedanib. N Engl J Med. 2015;372(13):1189–1191.
   PubMed Web of Science ®Google Scholar
• Galli JA, Pandya A, Vega-Olivo M, et al. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions. Respirology. 2017;22(6):1171–1178.
   PubMed Web of Science ®Google Scholar
• Ogura T, Taniguchi H, Azuma A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1382–1392.
   PubMed Web of Science ®Google Scholar
• Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011 Jun 24;10(7):507–519.
   PubMed Web of Science ®Google Scholar
• Samsdodd F. Target-based drug discovery: is something wrong? Drug Discov Today. 2005;10(2):139–147.
   PubMed Web of Science ®Google Scholar
• Li X, Ding Z, and Wu Z, et al. Targeting the TGF-beta signaling pathway for fibrosis therapy: a patent review (2015-2020). Expert Opin Ther Pat. 2021;31(8):723–743 . .
   PubMed Web of Science ®Google Scholar
• González-Gil I, Zian D, Vázquez-Villa H, et al. The status of the lysophosphatidic acid receptor type 1 (LPA1R). MedChemComm. 2015;6(1):13–23.
   Web of Science ®Google Scholar
• Meduri B, Pujar GV, Durai Ananda Kumar T, et al. Lysophosphatidic acid (LPA) receptor modulators: structural features and recent development. Eur J Med Chem. 2021 Oct 15;222:113574.
   PubMed Web of Science ®Google Scholar
• Hecht JH, Weiner JA, Post SR, et al. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Cell Biol. 1996;135(4):1071–1083.
   PubMed Web of Science ®Google Scholar
• Noguchi K, Ishii S, Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem. 2003 Jul 11;278(28):25600–25606.
   PubMed Web of Science ®Google Scholar
• Rancoule C, Pradere JP, Gonzalez J, et al. Lysophosphatidic acid-1-receptor targeting agents for fibrosis. Expert Opin Investig Drugs. 2011;20(5):657–667.
   PubMed Web of Science ®Google Scholar
• Geraldo LHM, Spohr T, Do Amaral RF, et al. Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies. Signal Transduct Target Ther. 2021 FEB 1. 6(1). DOI:10.1038/s41392-020-00367-5
   PubMed Web of Science ®Google Scholar
• KY FN, Chun J. A single receptor encoded by vzg-1/lpA1/edg-2 couples to G proteins and mediates multiple cellular responses to lysophosphatidic acid. Proc Natl Acad Sci U S A. 1998 May;95(11):6151–6156.
   PubMed Web of Science ®Google Scholar
• DM AS, Bleu T, Hallmark OG, et al. Molecular cloning of the human Edg2 protein and its identification as a functional cellular receptor for lysophosphatidic acid. Biochem Biophys Res Commun. 1997 Feb;231(3):619–622.
   PubMed Web of Science ®Google Scholar
• Kotarsky K, Boketoft A, Bristulf J, et al. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J Pharmacol Exp Ther. 2006;318(2):619–628.
   PubMed Web of Science ®Google Scholar
• Shea BS, Tager AM. Role of the lysophospholipid mediators lysophosphatidic acid and sphingosine 1-phosphate in lung fibrosis. Proc Am Thorac Soc. 2012;9(3):102–110.
   PubMedGoogle Scholar
• Funke M, Zhao Z, Xu Y, et al. The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury. Am J Respir Cell Mol Biol. 2012;46(3):355–364.
   PubMed Web of Science ®Google Scholar
• Tager AM, LaCamera P, Shea BS, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med. 2008;14(1):45–54.
   PubMed Web of Science ®Google Scholar
• Aoki J, Inoue A, Okudaira S. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta. 2008;1781(9):513–518.
   PubMed Web of Science ®Google Scholar
• Ikeda H, Yatomi Y. Autotaxin in liver fibrosis. Clin Chim Acta. 2012 Nov 20;413(23–24):1817–1821.
   PubMed Web of Science ®Google Scholar
• Sakai N, Bain G, Furuichi K, et al. The involvement of autotaxin in renal interstitial fibrosis through regulation of fibroblast functions and induction of vascular leakage. Sci Rep. 2019 May 15;9(1):7414. .
   PubMedGoogle Scholar
• Jeong KJ, Park SY, Cho KH, et al. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion. Oncogene. 2012 Sep 27;31(39):4279–4289.
   PubMed Web of Science ®Google Scholar
• Kim JH, Adelstein RS. LPA(1) -induced migration requires nonmuscle myosin II light chain phosphorylation in breast cancer cells. J Cell Physiol. 2011;226(11):2881–2893.
   PubMed Web of Science ®Google Scholar
• Loirand G. Rho kinases in health and disease: from basic science to translational research. Pharmacol Rev. 2015;67(4):1074–1095.
   PubMed Web of Science ®Google Scholar
• Feng Y, LoGrasso PV, Defert O, et al. Rho kinase (rock) inhibitors and their therapeutic potential. J Med Chem. 2016 Mar 24;59(6):2269–2300.
   PubMed Web of Science ®Google Scholar
• Kim S, Kim SA, Han J, et al. Rho-Kinase as a target for cancer therapy and its immunotherapeutic potential. Int J Mol Sci. 2021 Nov 29;22(23):12916.
   PubMed Web of Science ®Google Scholar
• Morgan-Fisher M, Wewer UM, Yoneda A. Regulation of ROCK activity in cancer. J Histochem Cytochem. 2013;61(3):185–198. .
   PubMed Web of Science ®Google Scholar
• Xie X, Peng J, Chang X, et al. Activation of RhoA/ROCK regulates NF-kappaB signaling pathway in experimental diabetic nephropathy. Mol Cell Endocrinol. 2013 Apr 30;369(1–2):86–97.
   PubMed Web of Science ®Google Scholar
• Knipe RS, Tager AM, Liao JK. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol Rev. 2015;67(1):103–117.
   PubMed Web of Science ®Google Scholar
• Sakai N, Chun J, Duffield JS, et al. Lysophosphatidic acid signaling through its receptor initiates profibrotic epithelial cell fibroblast communication mediated by epithelial cell derived connective tissue growth factor. Kidney Int. 2017;91(3):628–641.
   PubMed Web of Science ®Google Scholar
• Yu B, Sladojevic N, Blair JE, et al. Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening. Expert Opin Ther Targets. 2020;24(1):47–62.
   PubMed Web of Science ®Google Scholar
• Riches DW, Backos DS, Redente EF. ROCK and Rho: promising therapeutic targets to ameliorate pulmonary fibrosis. Am J Pathol. 2015;185(4):909–912.
   PubMed Web of Science ®Google Scholar
• Sakai N, Chun J, Duffield JS, et al. LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation. FASEB J. 2013;27(5):1830–1846.
   PubMed Web of Science ®Google Scholar
• Knipe RS, Probst CK, Lagares D, et al. The rho kinase isoforms ROCK1 and ROCK2 each contribute to the development of experimental pulmonary fibrosis. Am J Respir Cell Mol Biol. 2018;58(4):471–481.
   PubMed Web of Science ®Google Scholar
• Feng Y, LoGrasso PV. Rho kinase inhibitors: a patent review (2012 - 2013). Expert Opin Ther Pat. 2014;24(3):295–307.
   PubMed Web of Science ®Google Scholar
• Defert O, Boland S. Rho kinase inhibitors: a patent review (2014 - 2016). Expert Opin Ther Pat. 2017;27(4):507–515.
   PubMed Web of Science ®Google Scholar
• Hutchinson JH, Seiders TJ, Wang B, et al. inventors. Amira Pharmaceuticals Inc, USA. assignee. Preparation of isoxazolyl antagonists of lysophosphatidic acid receptors for use in treating cancer, fibrosis and Other Disorders. Patent WO2010141761. 2010.
   Google Scholar
• Brittain JE, Seiders TJ, Hutchinson JH, et al., inventors; Amira Pharmaceuticals, Inc., USA; Bristol-Myers Squibb Company. assignee. Polycyclic LPA1 antagonist and uses thereof patent WO2012078805. 2012.
   Google Scholar
• Buckman BO, Nicholas JB, Emayan K, et al., inventors; InterMune, Inc., USA. assignee. Preparation of N-heterocyclylcarbamates as lysophosphatidic acid (LPA) receptor antagonists patent WO2013025733. 2013.
   Google Scholar
• Palmer SM, Snyder L, Todd JL, et al. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis. Chest. 2018;154(5):1061–1069.
   PubMed Web of Science ®Google Scholar
• Hutchinson JH, Seiders TJ, Wang B, et al. inventors. Amira Pharmaceuticals Inc., USA. Assignee Preparation of Isoxazolyl Antagonists of Lysophosphatidic Acid Receptors for Disease Treatment. Patent WO2010077882. 2010.
   Google Scholar
• Cai J, Wei J, Li S, et al. AM966, an antagonist of lysophosphatidic acid receptor 1, increases lung microvascular endothelial permeability through activation of rho signaling pathway and phosphorylation of VE-Cadherin. Mediators Inflamm. 2017;2017:6893560.
   PubMed Web of Science ®Google Scholar
• Brittain JE, Seiders TJ, King CD, inventors; Amira Pharmaceuticals, Inc., USA. assignee. Preparation of carbonylaminoisoxazolylbiphenylacetic acid derivatives for use as lysophosphatidic acid receptor antagonist patent WO2011159550. 2011.
   Google Scholar
• Im DS. First-in-class antifibrotic therapy targeting type 1 lysophosphatidic acid receptor. Arch Pharm Res. 2012;35(6):945–948.
   PubMed Web of Science ®Google Scholar
• Swaney JS, Chapman C, Correa LD, et al. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br J Pharmacol. 2010;160(7):1699–1713.
   PubMed Web of Science ®Google Scholar
• Swaney JS, Chapman C, Correa LD, et al. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J Pharmacol Exp Ther. 2011;336(3):693–700.
   PubMed Web of Science ®Google Scholar
• Seiders TJ, Hutchinson JH, inventors; Amira Pharmaceuticals, Inc., USA. assignee. Inhalable formulations of lysophosphatdic acid receptor antagonists patent WO2011159633. 2011.
   Google Scholar
• Hutchinson JH, Dearmond IM, Seiders TJ, inventors; Amira Pharmaceuticals, Inc., USA. assignee. Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions patent WO2011159635. 2011.
   Google Scholar
• Seiders TJ, Zhao L, Arruda JM, et al., inventors; Amira Pharmaceuticals, Inc., USA. assignee. Preparation of biphenylisoxazole compounds as lysophosphatidic acid receptor antagonists patent WO2011041694. 2011.
   Google Scholar
• Clark R, Stearns BA, Zhao L, et al., inventors; Amira Pharmaceuticals, Inc., USA. assignee. Preparation of polycyclic isoxazole compounds as therapeutic lysophosphatidic acid receptor antagonists patent WO2011041461. 2011.
   Google Scholar
• Clark R, Stearns BA, Scott JM, et al. inventors. Amira Pharmaceuticals, Inc., USA. Assignee Preparation of Biphenylisoxazole Derivatives for Use as Lysophosphatidic Acid Receptor Antagonists. Patent WO2011041462. 2011.
   Google Scholar
• Seiders TJ, Zhao L, Arruda JM, et al., inventors; Amira Pharmaceuticals, Inc., USA. assignee. Preparation of isoxazole compounds as therapeutic lysophosphatidic acid receptor antagonists patent WO2011041729. 2011.
   Google Scholar
• Donnelly DJ, Bonacorsi SJ Jr., Cao K, et al., inventors; Bristol-Myers Squibb Company, USA; Yale University. assignee. Radioligands for imaging the lpa-1 receptor patent WO2015066456. 2015.
   Google Scholar
• Zhang M, Wang A, Inventors; KBP BioSciences Co., Ltd., Peop. Rep. China. assignee. Carboxylic acid derivative as lysophosphatidic acid (LPA) receptor antagonist with high selectivity for preparing drug for treating and/or preventing LPA-dependent or LPA-mediated diseases patent CN104418820. 2015.
   Google Scholar
• Seiders TJ, Wang B, Hutchinson JH, et al., inventors; Amira Pharmaceuticals, Inc., USA. assignee. Preparation of biphenyl-based compounds as therapeutic lysophosphatidic acid receptor antagonists and uses thereof patent WO2012078593. 2012.
   Google Scholar
• Tellew JE, Wang X, Wan Y, et al., inventors; IRM LLC, Bermuda; Novartis AG. assignee. Preparation of phenylethyl pyrazolylcarbamate derivatives as LPA receptor modulators patent WO2012138648. 2012.
   Google Scholar
• Beaton G, Tucci FC, Ravula SB, et al., inventors; Epigen Biosciences, Inc., USA. assignee. Preparation of heterocyclic compounds useful in the treatment of fibrosis, inflammatory, ocular, and nerve diseases patent WO2014145873. 2014.
   Google Scholar
• Ma T, Wu L, Zhang X, inventors; Eli Lilly and Company, USA; Lilly China Research and Development Co., Ltd. assignee. Preparation of substituted aminopyrazolylpyridylphenylcyclopropanecarboxylic acids as lysophosphatidic acid receptor 1 (LPAR1) inhibitors patent WO2019046239. 2019.
   Google Scholar
• Gabriel SD, Hamilton MM, Qian Y, et al., inventors; F. Hoffmann-La Roche AG, Switz.; Hoffmann-La Roche Inc., assignee. Preparation of pyrazole compounds as lysophosphatidic acid as (LPA) antagonists patent WO2013189862. 2013.
   Google Scholar
• Gabriel SD, Hamilton MM, Lucas MC, et al., inventors; F. Hoffmann-La Roche AG Hoffmann-La Roche Inc., assignee. Preparation of N-alkyltriazole compounds as as lysophosphatidic acid (LPA) antagonists patent WO2013189864. 2013.
   Google Scholar
• Gabriel SD, Hamilton MM, Qian Y, et al., inventors; F. Hoffmann-La Roche AG, Switz.; Hoffmann-La Roche Inc., assignee. Preparation of N-aryltriazole compounds as lysophosphatidic acid (LPA) antagonists patent WO2013189865. 2013.
   Google Scholar
• Qian Y, Hamilton M, Sidduri A, et al. Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts. J Med Chem. 2012 Sep 13;55(17):7920–7939.
   PubMed Web of Science ®Google Scholar
• Mishra RK, Panicker B, Tarrant JG, et al., inventors; Angion Biomedica Corp., USA. assignee. Preparation of small molecule anti-fibrotic compounds patent WO2013085824. 2013.
   Google Scholar
• Iwase N, Nishida H, Okudo M, et al., inventors; Ube Industries, Ltd., Japan. assignee. Preparation of halogen-substituted thiophene compounds as antagonists of lysophosphatidic acid (LPA) receptor patent WO2014104372. 2014.
   Google Scholar
• Iwase N, Nishida H, Okudo M, et al., inventors; UBE Industries, Ltd., Japan. assignee. Preparation of α-halo-substituted thiophene compound salts, and LPA receptor antagonists and pharmaceutical compositions containing them patent WO2015199234. 2015.
   Google Scholar
• Gill MW, Murphy BJ, Cheng PTW, et al. Mechanism of hepatobiliary toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: contrasts with BMS-986234 and BMS-986278. Toxicol Appl Pharmacol. 2022;26:115885.
   Google Scholar
• Cheng PTW, Kaltenbach RF 3rd, Zhang H, et al. Discovery of an oxycyclohexyl acid lysophosphatidic acid receptor 1 (LPA1) antagonist BMS-986278 for the treatment of pulmonary fibrotic diseases. J Med Chem. 2021 Nov 11;64(21):15549–15581.
   PubMed Web of Science ®Google Scholar
• Cheng PTW, Kaltenbach RF III, Zhang H, et al., inventors; Bristol-Myers Squibb Company, USA. assignee. (Carbamoyloxyisoxazolyl)aryloxy)cyclohexanecarboxylic acid as LPA antagonists and their preparation patent WO2019126084. 2019.
   Google Scholar
• Cheng PTW, Zhang H, Kaltenbach RF III, et al., inventors; Bristol-Myers Squibb Company, USA. assignee. Isoxazole carboxylic acid derivatives as LPA antagonists and their preparation patent WO2020257138. 2020.
   Google Scholar
• Cheng PTW, Kaltenbach RF III, Shi J, et al., inventors; Bristol-Myers Squibb Company, USA. assignee. Preparation of cyclopentyl acids as LPA antagonists patent WO2020060915. 2020.
   Google Scholar
• Shi Y, Cheng PTW, Wang Y, inventors; Bristol-Myers Squibb Company, USA. assignee. Carbamoyl-linked pyrazolylaryloxycyclohexanecarboxylic acid as LPA antagonists and their preparation patent WO2019126085. 2019.
   Google Scholar
• Cheng PTW, Li J, Shi Y, et al., inventors; Bristol-Myers Squibb Company, USA. assignee. ((Carbamoyloxypyrazolyl)aryloxy)cyclohexanecarboxylic acid as LPA antagonists and their preparation patent WO2019126098. 2019.
   Google Scholar
• Lou J, Chen Y, Peng W, et al., inventors; Wuhan LL Science and Technology Development Co., Ltd. Peop. Rep. China; Wuhan QR Pharmaceuticals Co., Ltd. assignee. Preparation of the lysophosphatidic acid receptor antagonists and their medical applications patent WO2020147739. 2020.
   Google Scholar
• Cheng PTW, Kaltenbach IRF, Li J, et al., inventors; Bristol-Myers Squibb Company, USA; Syngene International Limited. assignee. Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists and their preparation patent WO2017223016. 2017.
   Google Scholar
• Shi Y, Cheng PTW, Wang Y, et al., inventors; Bristol-Myers Squibb Company, USA. assignee. Preparation of triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists patent US2019185446. 2019.
   Google Scholar
• Cheng PTW, Corte JR, Donnelly DJ, et al., inventors; Bristol-Myers Squibb Company, USA. assignee. Radioligands for imaging the LPA1 receptor patent WO2020081410. 2020.
   Google Scholar
• Fox RJ, Guerrero CA, Dummeldinger M, et al., inventors; Bristol-Myers Squibb Company, USA. assignee. Process for preparing carbamoyloxymethyltriazolecyclohexyl acid compounds patent WO2020214545. 2020.
   Google Scholar
• Corte TJ, Lancaster L, Swigris JJ, et al. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA 1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respir Res. 2021;8(1):e001026.
   PubMed Web of Science ®Google Scholar
• Shi Y, Wang Y, Cheng PTW, et al., inventors; Bristol-Myers Squibb Company, USA. assignee. Cyclobutyl carboxylic acids as LPA antagonists and their preparation patent WO2020257139. 2020.
   Google Scholar
• Cheng PTW, Shi J, Tao S inventors; Bristol-Myers Squibb Company, USA. assignee , et al. Preparation of cycloheptyl acids as LPA antagonists patent WO2020060916. 2020.
   Google Scholar
• Cheng PTW, Zhang H, Kaltenbach RF III, et al., inventors; Bristol-Myers Squibb Company, USA. assignee. Triazole carboxylic acid derivatives as LPA antagonists and their preparation patent WO2020257135. 2020.
   Google Scholar
• Shi Y, Wang Y, Cheng PTW, inventors; Bristol-Myers Squibb Company, USA. assignee. Azine-substituted isozazolylaryloxycyclohexanecarboxylic acid as LPA antagonists and their preparation patent WO2019126086. 2019.
   Google Scholar
• Cheng PTW, Shi Y, Zhang H, et al. Azole-substituted isoxazolylaryloxycyclohexanecarboxylic acid as LPA antagonists and their preparation patent WO2019126087. 2019.
   Google Scholar
• Shi Y, Wang Y, Cheng PTW, et al., inventors; Bristol-Myers Squibb Company, USA. assignee. Azine-substituted triazolylaryloxycyclohexanecarboxylic acid as LPA antagonists and their preparation patent WO2019126093. 2019.
   Google Scholar
• Shi Y, Cheng PTW, Wang Y, et al., inventors; Bristol-Myers Squibb Company, USA. assignee. Triazolylaryloxycyclohexanecarboxylic acid as LPA antagonists and their preparation patent WO2019126094. 2019.
   Google Scholar
• Shi Y, Wang Y, Cheng PTW, et al., inventors; Bristol-Myers Squibb Company, USA. assignee. Azine-substituted pyrazolylaryloxycyclohexanecarboxylic acid as LPA antagonists and their preparation patent WO2019126089. 2019.
   Google Scholar
• Shi Y, Cheng PTW, Zhang H, et al., inventors; Bristol-Myers Squibb Company, USA. assignee. Cyclohexyl acid pyrazole azoles as LPA antagonists patent WO2019126103. 2019.
   Google Scholar
• Cheng PTW, Shi Y, Kaltenbach RF III, et al., inventors; Bristol-Myers Squibb Company, USA. assignee. Carbamoyl-linked isoxazolylaryloxycyclohexanecarboxylic acid as LPA antagonists and their preparation patent WO2019126099. 2019.
   Google Scholar
• Lou J, Chen Y, Peng W, et al., inventors; Wuhan LL Science and Technology Development Co., Ltd., Peop. Rep. China; Wuhan QR Pharmaceuticals Co., Ltd. assignee. Triazole compounds, and preparation method and use patent WO2020147740. 2020.
   Google Scholar
• Hutchinson JH, Seiders TJ, Arruda JM, inventors; Amira Pharmaceuticals, Inc., USA. assignee. Alkyne antagonists of lysophosphatidic acid receptors patent WO2010068775. 2010.
   Google Scholar
• An S, Li C, Zhou G, et al., inventors; Curegenix Inc., Peop. Rep. China. assignee. Isoxazolylcarbamate derivatives as lysophosphatidic acid receptor antagonists and their preparation and use for the treatment of LPA receptor-associated diseases patent WO2012100436. 2012.
   Google Scholar
• Buckman BO, Nicholas JB, Emayan K, et al., inventors; InterMune, Inc., USA. assignee. N-Heteroaryl carbamates as lysophosphatidic acid receptor antagonists and their preparation patent WO2014113485. 2014.
   Google Scholar
• Kawaminami E, Takahashi T, Kanayama T, et al., inventors; Astellas Pharma Inc., Japan. assignee. Preparation of heterocycle carboxamide compounds as lysophosphatidic acid (LPA) receptor antagonists patent WO2011037192. 2011.
   Google Scholar
• Kawaminami E, Takahashi T, Kanayama T, et al., inventors; Astellas Pharma Inc., Japan. assignee. Preparation of heterocycle-carboxamide compounds as LPA receptor antagonists patent WO2012039460. 2012.
   Google Scholar
• Budd D, Qian Y, Schoenfeld RC, et al., inventors; F. Hoffmann-La Roche AG, Switz.; Hoffmann-La Roche Inc. assignee. Preparation of substituted cyanopyrazole compounds as lysophosphatidic acid (LPA) antagonists patent WO2014037303. 2014.
   Google Scholar
• Sidduri A, Budd DC, Fuentes ME, et al. Discovery of novel non-carboxylic acid 5-amino-4-cyanopyrazole derivatives as potent and highly selective LPA1R antagonists. Bioorg Med Chem Lett. 2014 Sep 15;24(18):4450–4454.
   PubMed Web of Science ®Google Scholar
• Ellery J, Dickson L, Cheung T, et al. Identification of compounds acting as negative allosteric modulators of the LPA1 receptor. Eur J Pharmacol. 2018 Aug 15;833:8–15.
   PubMed Web of Science ®Google Scholar
• Buffham W, Canning H, Davenport R, et al., inventors; Takeda Pharmaceutical Company Limited, Japan; Takeda Cambridge Limited. assignee. Preparation of Amide Derivatives as Lysophosphatidic Acid Receptor Antagonists Patent WO2015025164. 2015.
   Google Scholar
• Black LA, Bunnelle WH, Chen D, et al., inventors; AbbVie Inc., USA. assignee. Preparation of tertiary amides as LPAR-1 modulators and therapeutic uses thereof patent WO2017177004. 2017.
   Google Scholar
• Bolli M, Brotschi C, Lescop C, et al., inventors; Idorsia Pharmaceuticals Ltd., Switz. assignee. Preparation of alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis patent WO2019234115. 2019.
   Google Scholar
• Shin DY, Choi JW, Jee J-G,inventors; Gachon University of Industry-Academic Cooperation Foundation, S. Korea; Kyungpook National University Industry-Academic Cooperation Foundation. assignee. Preparation of tetrahydropyrazolo[1,5-a]pyrazine phenylacetic acid derivatives for prevention or treatment of autoimmune diseases patent WO2020040326. 2020.
   Google Scholar
• Shin DY, Choi JU, Ji JG, inventors; Gachon University, Industry-University Cooperation Foundation, S. Korea; Kyungpook National University, Industry-Academic Cooperation Foundation. assignee. Preparation of benzoic acid derivative for the treatment of autoimmune disease patent KR2020023236. 2020.
   Google Scholar
• Shin DY, Choi JU, Ji JG, inventors; Gachon University, Industry-University Cooperation Foundation, S. Korea; Kyungpook National University, Industry-Academic Cooperation Foundation. assignee. Preparation of thiazolopiperazine derivatives for prevention or treatment of autoimmune diseases patent KR2020023237. 2020.
   Google Scholar
• Bolli M, Brotschi C, Lescop C, inventors; Idorsia Pharmaceuticals Ltd., Switz. assignee. Preparation of pyridin-3-yl derivatives as LPA1 receptor modulators patent WO2020254408. 2020.
   Google Scholar
• Cheng PTW, Shi J, Tao S, et al., inventors; Bristol-Myers Squibb Company, USA. assignee. Preparation of oxabicyclo acids as LPA antagonists patent WO2020060914. 2020.
   Google Scholar
• Bestvater BP, Du Z, Farand J, et al., inventors; Gilead Sciences, Inc., USA. assignee. Preparation of triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof patent WO2021097039. 2021.
   Google Scholar
• Wang H, Yang X, inventors; Minzu University of China, Peop. Rep. China; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences. assignee. Preparation of (benzoyl)piperazine derivative as LPAR1 antagonists and used for the treatment of cancer and tissue fibrosis patent CN113461640. 2021.
   Google Scholar
• Birker M, Lescop C, inventors; Idorsia Pharmaceuticals Ltd., Switz. assignee. Combination of an azetidine LPA1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases patent WO2021110805. 2021.
   Google Scholar
• Kuroda S, Kobayashi Y, Hatanaka K, et al., inventors; Taisho Pharmaceutical Co., Ltd., Japan. assignee. Urea compound for antagonizing LPA1 receptor, and scleroderma therapeutic/preventive agent patent WO2021020429. 2021.
   Google Scholar
• Ledein L, Leger B, Dees C, et al. Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse. Br J Pharmacol. 2020;177(18):4296–4309.
   PubMed Web of Science ®Google Scholar
• Moll S, Chaykovska L, Meier M, et al. Targeting the epithelial cells in fibrosis: a new concept for an old disease. Drug Discov Today. 2013;18(11–12):582–591.
   PubMed Web of Science ®Google Scholar
• Allanore Y, Distler O, Jagerschmidt A, et al. Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: a Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study. Arthritis Rheumatol. 2018;70(10):1634–1643.
   PubMed Web of Science ®Google Scholar
• Glunz PW, Zou Y, Quan ML, et al., inventors; Bristol-Myers Squibb Company, USA. assignee. Phthalazinones and isoquinolinones as ROCK inhibitors patent US2018162823. 2018.
   Google Scholar
• Orwat MJ, Pinto DJP, inventors B-MSC, et al. Preparation of phenylacetamides as inhibitors of ROCK patent WO2019014300. 2019.
   Google Scholar
• Pinto DJP, Maishal TK, inventors; Bristol-Myers Squibb Company, USA. assignee. Preparation of 5-membered aminoheterocyclic and 5,6- or 6,6-membered bicyclic aminoheterocyclic inhibitors of ROCK for the treatment of heart failure patent WO2019014303. 2019.
   Google Scholar
• Vokits BP, Shaw SA, inventors B-MSC, et al. Preparation of spiroheptanyl hydantoins as ROCK inhibitors patent WO2019014304. 2019.
   Google Scholar
• Glunz PW, Ladziata V, De Lucca I, et al., inventors; Bristol-Myers Squibb Company, USA. assignee. Preparation of 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK patent WO2019014308. 2019.
   Google Scholar
• Zhu Y, Dewnani SV, Ewing WR, inventors; Bristol-Myers Squibb Company, USA. assignee. Preparation of diazaspiro ROCK inhibitors patent WO2019089868. 2019.
   Google Scholar
• Accetta A, Rancati F, Capelli AM, et al., inventors; Chiesi Farmaceutici S.p.A., Italy. assignee. Preparation of tyrosine amide derivatives as Rho-kinase inhibitors patent WO2018138293. 2018.
   Google Scholar
• Accetta A, Rancati F, Capelli AM, et al., inventors; Chiesi Farmaceutici S.p.A., Italy. assignee. Preparation of tyrosine amide derivatives as Rho-kinase inhibitors patent US2020079774. 2020.
   Google Scholar
• Accetta A, Capelli AM, Rancati F, et al., inventors; Chiesi Farmaceutici S.p.A., Italy. assignee. Preparation of pyrrolopyridine derivatives and related heterocycles as Rho-kinase inhibitors useful in treatment of the various diseases patent WO2019048479. 2019.
   Google Scholar
• Accetta A, Rancati F, Clark DE, et al., inventors; Chiesi Farmaceutici S.p.A., Italy. assignee. Azaindole derivatives as Rho-kinase inhibitors and their preparation patent WO2019238628. 2019.
   Google Scholar
• Accetta A, Rancati F, Edwards C, et al., inventors; Chiesi Farmaceutici S.p.A., Italy. assignee. Preparation of oxadiazole derivatives as rho kinase inhibitors patent WO2019121233. 2019.
   Google Scholar
• Accetta A, Rancati F, Edwards C, et al., inventors; Chiesi Farmaceutici S.p.A., Italy. assignee. Preparation of azaindole derivatives as rho kinase inhibitors patent WO2019121406. 2019.
   Google Scholar
• Accetta A, Rancati F, Capelli AM, et al., inventors; Chiesi Farmaceutici S.p.A., Italy. assignee. Preparation of tyrosine amide derivatives as Rho-kinase inhibitors patent WO2020016129. 2020.
   Google Scholar
• Yao Y, Zhang L, Chen Z, et al., inventors; Medshine Discovery Inc., Peop. Rep. China. assignee. Isoquinolinylsulfonyl derivatives as RHO protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases patent WO2019015608. 2019.
   Google Scholar
• Wu L, Yin J, Wang C, et al., inventors; Medshine Discovery Inc., Peop. Rep. China. assignee. Process for preparation of pyrazole compound used as rho kinase inhibitor patent WO2019201296. 2019.
   Google Scholar
• Wu L, Yin J, Wang C, et al., inventors; Medshine Discovery Inc., Peop. Rep. China. assignee. Preparation of benzopyrazole compounds used as RHO kinase inhibitor patent WO2019201297. 2019.
   Google Scholar
• Wu L, Xiao Z, Jiang C, et al., inventors; Medshine Discovery Inc., Peop. Rep. China. assignee. Salt types, crystal forms, and preparation methods for benzopyrazole compounds as RHO kinase inhibitors patent WO2021073592. 2021.
   Google Scholar
• Skucas E, Liu KG, Kim J-I, et al., inventors; Kadmon Corporation, LLC, USA. assignee. Inhibitors of rho associated coiled-coil containing protein kinase patent WO2019018853. 2019.
   Google Scholar
• Skucas E, Liu KG, Kim J-I, et al., inventors; Kadmon Corporation, LLC, USA. assignee. Inhibitors of rho associated coiled-coil containing protein kinase patent WO2019018855. 2019.
   Google Scholar
• Skucas E, Liu KG, Kim J-I, et al., inventors; Kadmon Corporation, LLC, USA. assignee. Preparation of pyrimidine derivatives as inhibitors of rho associated coiled-coil containing protein kinase patent WO2019045824. 2019.
   Google Scholar
• A-H L, Dana D, Lim DS, et al., inventors; Angion Biomedica Corp., USA. assignee. Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors and their preparation patent WO2019046795. 2019.
   Google Scholar
• A-h L, Sakilam SK, Gadhiya SK, et al., inventors; Angion Biomedica Corp., USA. assignee. Preparation of ethynylheterocycles as rho-associated coiled-coil kinase (ROCK) inhibitors for the treatment of diseases patent WO2021016256. 2021.
   Google Scholar
• Liu J, Chen Y, Guo X, et al., inventors; Wuhan LL Science and Technology Development Co., Ltd., Peop. Rep. China. assignee. ROCK inhibitor and preparation method and application therefor patent WO2020211751. 2020.
   Google Scholar
• Li J, Lou J, Guo X, et al., inventors; Wuhan LL Science and Technology Development Co., Ltd., Peop. Rep. China. assignee. Preparation of the rock inhibitor and their medical applications patent WO2021093795. 2021.
   Google Scholar
• Zhou L, Zhao Q, Wang G, et al., inventors; Chengdu University of Technology, Peop. Rep. China. assignee. Hexahydro-2H-azepin-4-yloxybenzamide compound as Rho kinase inhibitor patent CN109180586. 2019.
   Google Scholar
• Jiang C, Huang H, Liu J, et al. Fasudil, a Rho-kinase inhibitor, attenuates bleomycin-induced pulmonary fibrosis in mice. Int J Mol Sci. 2012;13(7):8293–8307.
   PubMed Web of Science ®Google Scholar
• Mansour HM, Black S, Muralidharan P, inventors; University of Arizona, USA. assignee. Compositions and methods for delivering pharmaceutical agents such as fasudil dry powder for treating pulmonary hypertension patent WO2019084293. 2019.
   Google Scholar
• Zhao Y, Wang H, Jiang Y, et al., inventors; Beijing Tide Pharmaceutical Co., Ltd. Peop. Rep. China. assignee. Method for treating idiopathic pulmonary fibrosis patent WO2020259528. 2020.
   Google Scholar
• Mizunuma K, Ohdan H, Tashiro H, et al. ROCK inhibitor Y-27632 prevents primary graft non-function caused by warm ischemia/reperfusion in rat liver transplantation. Transpl Int. 2002;15(12):623–629.
   PubMed Web of Science ®Google Scholar
• Murata T, Arii S, Mori A, et al. Therapeutic significance of Y-27632, a Rho-kinase inhibitor, on the established liver fibrosis. J Surg Res. 2003;114(1):64–71.
   PubMed Web of Science ®Google Scholar
• Wu H, Wang G, inventors; Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., Peop. Rep. China. assignee. Y27632 prodrug and its preparation method and application in preparation of drug for treating liver fibrosis patent CN110590838. 2019.
   Google Scholar
• Dong M, Yan BP, Liao JK, et al. Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today. 2010;15(15–16):622–629.
   PubMed Web of Science ®Google Scholar
• Cui Q, Zhang Y, Chen H, et al. Rho kinase: a new target for treatment of cerebral ischemia/reperfusion injury. Neural Regen Res. 2013 May 5;8(13):1180–1189.
   PubMed Web of Science ®Google Scholar